The trial included patients with previously untreated locally advanced or metastatic urothelial cancer, a form of bladder cancer that has spread to surrounding organs, muscles, or other body parts.
The EV-302 trial enrolled patients with previously untreated patients eligible for cisplatin- or carboplatin-containing chemotherapy regardless of PD-L1 status.
The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy.
An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis.
The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients.
Price Action: SGEN shares are up 3.54% at $213.69 on the last check Friday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
